| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 25 | 2022 | 371 | 5.610 |
Why?
|
| Glioma | 9 | 2022 | 140 | 2.740 |
Why?
|
| Biomarkers, Tumor | 11 | 2019 | 508 | 2.370 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2020 | 444 | 2.300 |
Why?
|
| Glioblastoma | 6 | 2020 | 219 | 1.860 |
Why?
|
| Meningioma | 4 | 2017 | 54 | 1.670 |
Why?
|
| Isocitrate Dehydrogenase | 10 | 2022 | 18 | 1.630 |
Why?
|
| Mitotic Index | 3 | 2015 | 14 | 1.560 |
Why?
|
| Mutation | 11 | 2020 | 1213 | 1.400 |
Why?
|
| Meningeal Neoplasms | 3 | 2017 | 42 | 1.200 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2022 | 29 | 1.140 |
Why?
|
| DNA Methylation | 6 | 2019 | 192 | 0.920 |
Why?
|
| Prostate | 2 | 2014 | 116 | 0.910 |
Why?
|
| Astrocytoma | 5 | 2022 | 30 | 0.750 |
Why?
|
| X-linked Nuclear Protein | 2 | 2019 | 4 | 0.740 |
Why?
|
| Neurosurgical Procedures | 3 | 2019 | 98 | 0.720 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 54 | 0.700 |
Why?
|
| Endolymphatic Sac | 1 | 2018 | 6 | 0.680 |
Why?
|
| Ear Neoplasms | 1 | 2018 | 13 | 0.670 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 307 | 0.670 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 110 | 0.650 |
Why?
|
| Histones | 3 | 2018 | 111 | 0.650 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 778 | 0.620 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 206 | 0.600 |
Why?
|
| Epigenomics | 1 | 2017 | 29 | 0.590 |
Why?
|
| Sarcoma, Myeloid | 1 | 2016 | 11 | 0.580 |
Why?
|
| Precision Medicine | 2 | 2016 | 111 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 467 | 0.560 |
Why?
|
| Humans | 48 | 2022 | 68525 | 0.510 |
Why?
|
| Mitosis | 1 | 2015 | 76 | 0.510 |
Why?
|
| Seizures | 4 | 2021 | 279 | 0.500 |
Why?
|
| Prognosis | 10 | 2019 | 2093 | 0.500 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 22 | 0.490 |
Why?
|
| Neurogenesis | 1 | 2014 | 32 | 0.480 |
Why?
|
| Middle Aged | 25 | 2021 | 21119 | 0.470 |
Why?
|
| Male | 32 | 2021 | 37281 | 0.460 |
Why?
|
| Young Adult | 16 | 2019 | 5708 | 0.460 |
Why?
|
| Axons | 1 | 2014 | 139 | 0.440 |
Why?
|
| Drug Discovery | 1 | 2014 | 94 | 0.440 |
Why?
|
| Female | 30 | 2021 | 38015 | 0.440 |
Why?
|
| Ependymoma | 4 | 2017 | 13 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 369 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 756 | 0.420 |
Why?
|
| Adolescent | 17 | 2019 | 8903 | 0.420 |
Why?
|
| Adult | 22 | 2021 | 21375 | 0.410 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2016 | 28 | 0.400 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1172 | 0.390 |
Why?
|
| Oligodendroglioma | 2 | 2021 | 18 | 0.390 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1070 | 0.350 |
Why?
|
| Decision Making | 1 | 2012 | 410 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2019 | 28 | 0.340 |
Why?
|
| Ganglioglioma | 2 | 2022 | 11 | 0.340 |
Why?
|
| Aged | 16 | 2021 | 14842 | 0.330 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 349 | 0.320 |
Why?
|
| Child | 12 | 2022 | 6400 | 0.320 |
Why?
|
| Infant | 7 | 2019 | 2891 | 0.310 |
Why?
|
| Ki-67 Antigen | 3 | 2017 | 28 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 2222 | 0.300 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4843 | 0.300 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 25 | 0.280 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 170 | 0.270 |
Why?
|
| Retrospective Studies | 10 | 2022 | 7264 | 0.270 |
Why?
|
| Nerve Tissue Proteins | 3 | 2018 | 290 | 0.270 |
Why?
|
| Sarcoma | 2 | 2016 | 70 | 0.260 |
Why?
|
| Electroencephalography | 4 | 2021 | 418 | 0.260 |
Why?
|
| Signal Transduction | 5 | 2019 | 2688 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 332 | 0.250 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 211 | 0.250 |
Why?
|
| Child, Preschool | 8 | 2019 | 3185 | 0.240 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 159 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 129 | 0.220 |
Why?
|
| Survival Analysis | 4 | 2017 | 714 | 0.200 |
Why?
|
| Medical Oncology | 1 | 2021 | 110 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.190 |
Why?
|
| DNA Copy Number Variations | 2 | 2019 | 27 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2019 | 8 | 0.180 |
Why?
|
| Central Nervous System Cysts | 1 | 2019 | 5 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 11 | 0.180 |
Why?
|
| Aneuploidy | 1 | 2019 | 21 | 0.180 |
Why?
|
| Siblings | 1 | 2019 | 34 | 0.180 |
Why?
|
| Chromosome Deletion | 2 | 2019 | 41 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 36 | 0.170 |
Why?
|
| PAX2 Transcription Factor | 1 | 2018 | 11 | 0.170 |
Why?
|
| Keratins | 1 | 2018 | 48 | 0.170 |
Why?
|
| Brain | 2 | 2020 | 2175 | 0.170 |
Why?
|
| DNA Helicases | 1 | 2019 | 64 | 0.170 |
Why?
|
| Status Epilepticus | 1 | 2019 | 74 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 1174 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2019 | 2356 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3256 | 0.160 |
Why?
|
| Trans-Activators | 1 | 2019 | 237 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1465 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 222 | 0.160 |
Why?
|
| DNA Modification Methylases | 2 | 2018 | 24 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 411 | 0.150 |
Why?
|
| Neuroblastoma | 1 | 2018 | 109 | 0.150 |
Why?
|
| DNA Repair Enzymes | 2 | 2018 | 53 | 0.150 |
Why?
|
| Computational Biology | 1 | 2018 | 190 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 331 | 0.150 |
Why?
|
| Neurocytoma | 1 | 2016 | 3 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 376 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 23 | 0.140 |
Why?
|
| Olfaction Disorders | 1 | 2018 | 100 | 0.140 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2016 | 2 | 0.140 |
Why?
|
| Papilloma, Choroid Plexus | 1 | 2016 | 2 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 306 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2018 | 194 | 0.140 |
Why?
|
| Gliosarcoma | 1 | 2015 | 4 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 100 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 68 | 0.140 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2015 | 6 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.130 |
Why?
|
| Telomerase | 1 | 2015 | 85 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1139 | 0.130 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 4 | 0.130 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2014 | 2 | 0.130 |
Why?
|
| ErbB Receptors | 2 | 2015 | 239 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 32 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 231 | 0.130 |
Why?
|
| Lung | 1 | 2020 | 849 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2014 | 432 | 0.130 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 47 | 0.130 |
Why?
|
| Phenotype | 2 | 2017 | 946 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 46 | 0.120 |
Why?
|
| Neck | 1 | 2014 | 62 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 267 | 0.120 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 40 | 0.120 |
Why?
|
| Carcinoma | 1 | 2016 | 215 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cytokines | 1 | 2018 | 866 | 0.120 |
Why?
|
| Polyradiculoneuropathy | 1 | 2013 | 3 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 274 | 0.120 |
Why?
|
| Olfactory Nerve Diseases | 1 | 2013 | 1 | 0.120 |
Why?
|
| Colloid Cysts | 1 | 2013 | 3 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 186 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 614 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.120 |
Why?
|
| Prostatectomy | 1 | 2014 | 87 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 151 | 0.110 |
Why?
|
| CpG Islands | 1 | 2012 | 51 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2019 | 144 | 0.110 |
Why?
|
| Disease Progression | 2 | 2015 | 1037 | 0.110 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2011 | 5 | 0.100 |
Why?
|
| Point Mutation | 1 | 2012 | 97 | 0.100 |
Why?
|
| Parotid Gland | 1 | 2011 | 33 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 1199 | 0.100 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2011 | 40 | 0.100 |
Why?
|
| Proteins | 1 | 2014 | 473 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2013 | 434 | 0.100 |
Why?
|
| Animals | 3 | 2019 | 20877 | 0.100 |
Why?
|
| Time Factors | 2 | 2021 | 4655 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 536 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 1055 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 785 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 592 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 415 | 0.080 |
Why?
|
| United States | 1 | 2019 | 7335 | 0.070 |
Why?
|
| Apoptosis | 1 | 2014 | 1640 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 1609 | 0.070 |
Why?
|
| Transcriptome | 2 | 2018 | 164 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 110 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1054 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 498 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2021 | 7028 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 211 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.050 |
Why?
|
| Oncogene Fusion | 1 | 2019 | 1 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 14 | 0.040 |
Why?
|
| Optic Nerve Diseases | 1 | 2019 | 31 | 0.040 |
Why?
|
| Nausea | 1 | 2019 | 47 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2077 | 0.040 |
Why?
|
| Headache | 1 | 2019 | 68 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 104 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 125 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2019 | 94 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 438 | 0.040 |
Why?
|
| Unsupervised Machine Learning | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 51 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 82 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 929 | 0.040 |
Why?
|
| Extremities | 1 | 2016 | 49 | 0.040 |
Why?
|
| Methylation | 1 | 2016 | 56 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 42 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 92 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 156 | 0.030 |
Why?
|
| World Health Organization | 1 | 2015 | 53 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2014 | 4 | 0.030 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 18 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 30 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 24 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 948 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 127 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 319 | 0.030 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Ethmoid Sinus | 1 | 2013 | 15 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 230 | 0.030 |
Why?
|
| Hydrolases | 1 | 2013 | 20 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 791 | 0.030 |
Why?
|
| Craniotomy | 1 | 2013 | 33 | 0.030 |
Why?
|
| Leg | 1 | 2014 | 191 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 595 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 216 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 799 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 58 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 164 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2013 | 41 | 0.030 |
Why?
|
| Autoantigens | 1 | 2013 | 91 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1860 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 218 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 114 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 562 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 142 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 163 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2012 | 144 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 76 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 626 | 0.020 |
Why?
|
| Melanoma | 1 | 2014 | 335 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 710 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2453 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2004 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1034 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1446 | 0.020 |
Why?
|
| Stroke | 1 | 2019 | 2161 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 8472 | 0.010 |
Why?
|